Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (61-70 of 151) with videos related to

Pageof 16
Sort By:
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
British Journal of Haematology|March 17, 2010
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)Sergio Amadori, Stefan Suciu, Dominik Selleslag, et al.
Haematologica|July 6, 2014
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTYves Chalandon, Jakob R Passweg, Cesare Guglielmi, et al.
Experimental Cell Research|September 8, 2004
Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosisAniek O de Graaf, Lambert P van den Heuvel, Henry B P M Dijkman, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
British Journal of Haematology|July 17, 2009
Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survivalTheo de Witte, Ronald Brand, Anja van Biezen, et al.
Cancer Medicine|December 19, 2022
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT projectFabio Efficace, Karin Koinig, Francesco Cottone, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantationAlois Gratwohl, Ronald Brand, Dietger Niederwieser, et al.
Pageof 16

Showing results (61-70 of 151) with videos related to

Sort By:
Pageof 16
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.
British Journal of Haematology|March 17, 2010
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)Sergio Amadori, Stefan Suciu, Dominik Selleslag, et al.
Haematologica|July 6, 2014
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTYves Chalandon, Jakob R Passweg, Cesare Guglielmi, et al.
Experimental Cell Research|September 8, 2004
Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosisAniek O de Graaf, Lambert P van den Heuvel, Henry B P M Dijkman, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
British Journal of Haematology|July 17, 2009
Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survivalTheo de Witte, Ronald Brand, Anja van Biezen, et al.
Cancer Medicine|December 19, 2022
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT projectFabio Efficace, Karin Koinig, Francesco Cottone, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantationAlois Gratwohl, Ronald Brand, Dietger Niederwieser, et al.
Pageof 16